US6372755B2
(en)
|
1997-07-11 |
2002-04-16 |
Toray Industries, Inc. |
Stable medicinal compositions containing 4,5-epoxymorphinan derivatives
|
US8936808B1
(en)
|
1997-12-22 |
2015-01-20 |
Purdue Pharma L.P. |
Opioid agonist/opioid antagonist/acetaminophen combinations
|
US6277384B1
(en)
|
1997-12-22 |
2001-08-21 |
Euro-Celtique S.A. |
Opioid agonist/antagonist combinations
|
US6375957B1
(en)
|
1997-12-22 |
2002-04-23 |
Euro-Celtique, S.A. |
Opioid agonist/opioid antagonist/acetaminophen combinations
|
US6475494B2
(en)
|
1997-12-22 |
2002-11-05 |
Euro-Celtique S.A. |
Opioid agonist/antagonist combinations
|
US6627635B2
(en)
|
1997-12-22 |
2003-09-30 |
Euro-Celtique S.A. |
Method of preventing abuse of opioid dosage forms
|
US6228863B1
(en)
|
1997-12-22 |
2001-05-08 |
Euro-Celtique S.A. |
Method of preventing abuse of opioid dosage forms
|
US6696066B2
(en)
|
1997-12-22 |
2004-02-24 |
Euro-Celtique S.A. |
Opioid agonist/antagonist combinations
|
US8932630B1
(en)
|
1997-12-22 |
2015-01-13 |
Purdue Pharma L.P |
Opioid agonist/antagonist combinations
|
US9205082B2
(en)
|
1997-12-22 |
2015-12-08 |
Purdue Pharma L.P. |
Opioid agonist/antagonist combinations
|
US8822487B2
(en)
|
1997-12-22 |
2014-09-02 |
Purdue Pharma L.P. |
Opioid agonist/opioid antagonist/acetaminophen combinations
|
US8673355B2
(en)
|
1997-12-22 |
2014-03-18 |
Purdue Pharma L.P. |
Opioid agonist/antagonist combinations
|
US9474750B2
(en)
|
1997-12-22 |
2016-10-25 |
Purdue Pharma L.P. |
Opioid agonist/opioid antagonist/acetaminophen combinations
|
US8105631B2
(en)
|
1997-12-22 |
2012-01-31 |
Purdue Pharma L.P. |
Opioid agonist/antagonist combinations
|
US8236351B2
(en)
|
2000-02-08 |
2012-08-07 |
Purdue Pharma L.P. |
Tamper-resistant oral opioid agonist formulations
|
US8357399B2
(en)
|
2000-02-08 |
2013-01-22 |
Purdue Pharma L.P. |
Tamper-resistant oral opioid agonist formulations
|
US7842309B2
(en)
|
2000-02-08 |
2010-11-30 |
Purdue Pharma L.P. |
Tamper-resistant oral opioid agonist formulations
|
US7842311B2
(en)
|
2000-02-08 |
2010-11-30 |
Purdue Pharma L.P. |
Tamper-resistant oral opioid agonist formulations
|
US6696088B2
(en)
|
2000-02-08 |
2004-02-24 |
Euro-Celtique, S.A. |
Tamper-resistant oral opioid agonist formulations
|
US8936812B2
(en)
|
2000-02-08 |
2015-01-20 |
Purdue Pharma L.P. |
Tamper-resistant oral opioid agonist formulations
|
US6716449B2
(en)
|
2000-02-08 |
2004-04-06 |
Euro-Celtique S.A. |
Controlled-release compositions containing opioid agonist and antagonist
|
US9278073B2
(en)
|
2000-02-08 |
2016-03-08 |
Purdue Pharma L.P. |
Tamper-resistant oral opioid agonist formulations
|
US10350173B2
(en)
|
2000-02-08 |
2019-07-16 |
Purdue Pharma L.P. |
Tamper resistant oral opioid agonist formulations
|
US9456989B2
(en)
|
2000-02-08 |
2016-10-04 |
Purdue Pharma L.P. |
Tamper-resistant oral opioid agonist formulations
|
US7658939B2
(en)
|
2000-02-08 |
2010-02-09 |
Purdue Pharma L.P. |
Tamper-resistant oral opioid agonist formulations
|
US8586088B2
(en)
|
2000-02-08 |
2013-11-19 |
Purdue Pharma L.P. |
Tamper-resistant oral opioid agonist formulations
|
US10588865B2
(en)
|
2000-02-08 |
2020-03-17 |
Purdue Pharma L.P. |
Tamper resistant oral opioid agonist formulations
|
US9801828B2
(en)
|
2000-02-08 |
2017-10-31 |
Purdue Pharma L.P. |
Tamper resistant oral opioid agonist formulations
|
US7682632B2
(en)
|
2000-02-08 |
2010-03-23 |
Purdue Pharma L.P. |
Tamper-resistant oral opioid agonist formulations
|
US9345701B1
(en)
|
2001-05-11 |
2016-05-24 |
Purdue Pharma L.P. |
Abuse-resistant controlled-release opioid dosage form
|
US9283221B2
(en)
|
2001-05-11 |
2016-03-15 |
Purdue Pharma L.P. |
Abuse-resistant controlled-release opioid dosage form
|
US9283216B2
(en)
|
2001-05-11 |
2016-03-15 |
Purdue Pharma L.P. |
Abuse-resistant controlled-release opioid dosage form
|
US9358230B1
(en)
|
2001-05-11 |
2016-06-07 |
Purdue Pharma L.P. |
Abuse-resistant controlled-release opioid dosage form
|
US9168252B2
(en)
|
2001-05-11 |
2015-10-27 |
Purdue Pharma L.P. |
Abuse-resistant controlled-release opioid dosage form
|
US9161937B2
(en)
|
2001-05-11 |
2015-10-20 |
Purdue Pharma L.P. |
Abuse-resistant controlled-release opioid dosage form
|
US9084729B2
(en)
|
2001-05-11 |
2015-07-21 |
Purdue Pharma L.P. |
Abuse-resistant controlled-release opioid dosage form
|
US9056051B2
(en)
|
2001-05-11 |
2015-06-16 |
Purdue Pharma L.P. |
Abuse-resistant controlled-release opioid dosage form
|
US9480685B2
(en)
|
2001-05-11 |
2016-11-01 |
Purdue Pharma L.P. |
Abuse-resistant controlled-release opioid dosage form
|
US9511066B2
(en)
|
2001-05-11 |
2016-12-06 |
Purdue Pharma L.P. |
Abuse-resistant controlled-release opioid dosage form
|
US8969369B2
(en)
|
2001-05-11 |
2015-03-03 |
Purdue Pharma L.P. |
Abuse-resistant controlled-release opioid dosage form
|
US7943173B2
(en)
|
2001-07-18 |
2011-05-17 |
Purdue Pharma L.P. |
Pharmaceutical combinations of oxycodone and naloxone
|
US8231901B2
(en)
|
2001-08-06 |
2012-07-31 |
Purdue Pharma L.P. |
Opioid agonist formulations with releasable and sequestered antagonist
|
US7914818B2
(en)
|
2001-08-06 |
2011-03-29 |
Purdue Pharma L.P. |
Opioid agonist formulations with releasable and sequestered antagonist
|
US8518443B2
(en)
|
2001-08-06 |
2013-08-27 |
Purdue Pharma, L.P. |
Opioid agonist formulations with releasable and sequestered antagonist
|
US8465774B2
(en)
|
2001-08-06 |
2013-06-18 |
Purdue Pharma L.P. |
Sequestered antagonist formulations
|
US9949930B2
(en)
|
2001-08-06 |
2018-04-24 |
Purdue Pharma L.P. |
Opioid agonist formulations with releasable and sequestered antagonist
|
US8815287B2
(en)
|
2001-08-06 |
2014-08-26 |
Purdue Pharma L.P. |
Opiod agonist formulations with releasable and sequestered antagonist
|
US8758825B2
(en)
|
2001-08-06 |
2014-06-24 |
Purdue Pharma L.P. |
Sequestered antagonist formulations
|
US9655855B2
(en)
|
2002-04-05 |
2017-05-23 |
Purdue Pharma L.P. |
Matrix for sustained, invariant and independent release of active compounds
|
US10420762B2
(en)
|
2002-04-05 |
2019-09-24 |
Purdue Pharma L.P. |
Pharmaceutical preparation containing oxycodone and naloxone
|
US8846090B2
(en)
|
2002-04-05 |
2014-09-30 |
Euro-Celtique S.A. |
Matrix for sustained, invariant and independent release of active compounds
|
US9555000B2
(en)
|
2002-04-05 |
2017-01-31 |
Purdue Pharma L.P. |
Pharmaceutical preparation containing oxycodone and naloxone
|
US8846091B2
(en)
|
2002-04-05 |
2014-09-30 |
Euro-Celtique S.A. |
Matrix for sustained, invariant and independent release of active compounds
|
US9907793B2
(en)
|
2002-04-05 |
2018-03-06 |
Purdue Pharma L.P. |
Pharmaceutical preparation containing oxycodone and naloxone
|
US8685444B2
(en)
|
2002-09-20 |
2014-04-01 |
Alpharma Pharmaceuticals Llc |
Sequestering subunit and related compositions and methods
|
US8685443B2
(en)
|
2002-09-20 |
2014-04-01 |
Alpharma Pharmaceuticals Llc |
Sequestering subunit and related compositions and methods
|
US10092519B2
(en)
|
2003-04-21 |
2018-10-09 |
Purdue Pharma L.P. |
Pharmaceutical products
|
US9149436B2
(en)
|
2003-04-21 |
2015-10-06 |
Purdue Pharma L.P. |
Pharmaceutical product comprising a sequestered agent
|
US8518925B2
(en)
|
2004-06-08 |
2013-08-27 |
Euro-Celtique S.A. |
Opioids for the treatment of the chronic obstructive pulmonary disease (COPD)
|
US10258235B2
(en)
|
2005-02-28 |
2019-04-16 |
Purdue Pharma L.P. |
Method and device for the assessment of bowel function
|
US8846104B2
(en)
|
2006-06-19 |
2014-09-30 |
Alpharma Pharmaceuticals Llc |
Pharmaceutical compositions for the deterrence and/or prevention of abuse
|
US8158156B2
(en)
|
2006-06-19 |
2012-04-17 |
Alpharma Pharmaceuticals, Llc |
Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist
|
US7682633B2
(en)
|
2006-06-19 |
2010-03-23 |
Alpharma Pharmaceuticals, Llc |
Pharmaceutical composition
|
US7682634B2
(en)
|
2006-06-19 |
2010-03-23 |
Alpharma Pharmaceuticals, Llc |
Pharmaceutical compositions
|
US8877247B2
(en)
|
2006-06-19 |
2014-11-04 |
Alpharma Pharmaceuticals Llc |
Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist
|